Exelixis | EXEL - Debt


Exelixis reported $162.2M in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Amgen USD 57.3B 19M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bayer EUR 36.45B 2.93B Dec/2025
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Cytokinetics USD 1.27B 18.17M Jun/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Exelixis USD 162.2M 3.73M Sep/2026
Genmab DKK 5.35B 5.2B Mar/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 62.67B 523M Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sanofi EUR 23.58B 3.56B Jun/2026
Takeda JPY 4.58T 364.32B Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Xencor USD 170.11M 5.06M Jun/2026